To address this, a clinical trial is now planned to explore the efficacy of AZD4547, both in monotherapy and in combination with the anti-PDL1 antibody MEDI4736, in advanced UC patients with FGFR3 mutations or fusion-positive tumours, and a future opportunity might be to expand these studies to patients with elevated FGFR and/or ligand expression. This evidence concerns the gene CD274 and neoplasm.